COMP-SR: Composition & Function of Sarcoplasmic Reticulum in Persons With the Metabolic Syndrome

Sponsor
Washington University School of Medicine (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT02122666
Collaborator
(none)
100
1
105
1

Study Details

Study Description

Brief Summary

The investigators previous research has suggested that lipid (fatty) composition in the muscle cells of mice plays a key role in their insulin sensitivity. The purpose of this study is to determine whether these specific fat signatures translate to humans by comparing the muscle of healthy patients to those with pre-diabetes, or "the metabolic syndrome".

Condition or Disease Intervention/Treatment Phase
  • Procedure: muscle biopsy

Detailed Description

The Comp-SR study explores the role of lipid metabolism in key metabolic pathways in skeletal muscle. It is a translation of previous research done in mice studying the effects and functions of certain key enzymes involved in lipid metabolism found to be associated with insulin resistance. These enzymes are fatty acid synthase (FAS), choline/ethanolamine phosphotransferase 1 (CEPT1) and sarcoplasmic-endoplasmic reticulum ATPase (SERCA). Based on the investigators research, it appears that the activity and function of these enzymes determines the ratio of certain phospholipids in the sarcoplasmic reticulum (SR), namely phosphatidylethanolamine (PE) and phosphatidylcholine (PC). Furthermore, the investigators have found that the ratio of these phospholipids correlates with the mouse's sensitivity to insulin.

Based on the muscle biopsies of four healthy persons, it was found that human muscle contains similar phospholipids and phospholipid ratios to mice. It is hypothesized that these phospholipid signatures may be predictive of the metabolic status of humans as well. The specific aims of this study are to determine if the composition and function of the sarcoplasmic reticulum is altered in persons with the metabolic syndrome compared to lean controls. This knowledge could provide new understanding of impediments to effective therapy, novel biomarkers of disease progression, and innovative treatment targets for diabetes.

Study Design

Study Type:
Observational
Anticipated Enrollment :
100 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Modulating Physiologic Effects Of Phospholipid Metabolism In Obesity And Diabetes; AIM 4: Composition and Function of Sarcoplasmic Reticulum in Persons With the Metabolic Syndrome
Study Start Date :
Mar 1, 2014
Anticipated Primary Completion Date :
Dec 1, 2022
Anticipated Study Completion Date :
Dec 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Metabolic Syndrome

Muscle biopsy to determine sarcoplasmic reticulum composition and function, Oral Glucose tolerance test with insulin levels at time points to determine Insulin sensitivity, DEXA scan to determine lean muscle and fat mass

Procedure: muscle biopsy
A member of the study team will obtain a small sample of muscle tissue from the patient's thigh (vastus lateralis muscle).

Control

Muscle biopsy to determine sarcoplasmic reticulum composition and function, Oral Glucose tolerance test with insulin levels at time points to determine Insulin sensitivity, DEXA scan to determine lean muscle and fat mass

Procedure: muscle biopsy
A member of the study team will obtain a small sample of muscle tissue from the patient's thigh (vastus lateralis muscle).

Outcome Measures

Primary Outcome Measures

  1. Sarcoplasmic Reticulum Composition [Study Visit Week 4]

    We will take a muscle tissue sample from the subject's thigh (vastus lateralis) to quantify phosphatidylcholine to phosphatidylethanolamine ratio of the sarcoplasmic reticulum, as well as SERCA activity and FAS and CEPT1 quantity in the sample.

Secondary Outcome Measures

  1. Insulin Sensitivity [Study visit week 4]

    We will perform an oral glucose tolerance test with insulin levels obtained at each time point to determine the Matsuda index, an estimation of insulin sensitivity.

  2. Lean and Fat Body Mass [Study Visit week 4]

    We will perform a Duel Energy X-ray absorptiometry (DEXA) scan to approximate lean and fat body mass of study subjects.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes

Control subjects

Inclusion:

Sedentary: No routine exercise, walking <10,000 steps per day Age >18 and <65 Body Mass Index (BMI) <32 Healthy by physical exam (patient is devoid of major acute or chronic illness) No significant abnormality in screening labs

Exclusion:

Currently on any significant prescription medications other than oral contraceptives in women Currently Pregnant Current Tobacco Use

Subjects with the Metabolic Syndrome

Inclusion:

Sedentary: No routine exercise, walking <10,000 steps per day Age >18 and <65 Body Mass Index (BMI) >30

Meet at least three of the following Adult Treatment Panel (ATP) III criteria for the metabolic syndrome:

waist circumference > or = 40 inches in men, > or = 35 inches in women blood triglycerides

or = 150 mg/dL blood HDL cholesterol <40 mg/dL in men, <50 in women blood pressure > or = 130 mmHg systolic, or > or = 85 mmHg diastolic fasting blood sugar > or = 100 mg/dL

Exclusion:

Diagnosed with Type 2 diabetes, coronary artery disease, cancer, liver, lung, or kidney disease or any other major illness

Currently on any significant prescription medications other than:

oral contraceptives in women More than two standard medication for stage 1 hypertension in men or women (blood pressure 140-159/90-99) Currently Pregnant Current Tobacco Use

Contacts and Locations

Locations

Site City State Country Postal Code
1 Washington University School of Medicine Saint Louis Missouri United States 63110

Sponsors and Collaborators

  • Washington University School of Medicine

Investigators

  • Principal Investigator: Clay F. Semenkovich, M.D., Washington University School of Medicine
  • Principal Investigator: Janet B McGill, M.D., Washington University School of Medicine

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

Responsible Party:
Washington University School of Medicine
ClinicalTrials.gov Identifier:
NCT02122666
Other Study ID Numbers:
  • 201311099
First Posted:
Apr 24, 2014
Last Update Posted:
Jul 21, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Keywords provided by Washington University School of Medicine
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 21, 2022